Search Bar & Filters
Found 2 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating the effects of elecoglipron compared with a placebo in adults with chronic kidney disease CKD, including those with and without type 2 diabetes mellitus T2DM. This Phase III, randomized, double-blind, placebo-controlled study includes participants who are receiving standard care treatments for CKD, including the SGLT2 inhibitor dapagliflozin. The study aims to determine whether elecoglipron can reduce the risk of kidney function decline, end-stage kidney disease, and mortality. Participants will be randomly assigned to receive either elecoglipron tablets or matching placebo tablets once daily. The study is multicenter and involves parallel groups. The treatment period and evaluation are event-driven and may last up to 4.5 years. Both study groups will continue their background therapies for CKD alongside the study medication or placebo. During the study, participants will be monitored regularly to assess kidney function, cardiovascular events, and overall health outcomes, including mortality. Researchers will measure sustained declines in estimated glomerular filtration rate eGFR, occurrence of end-stage kidney disease, cardiovascular death, heart failure hospitalizations, and other related outcomes. The study includes safety monitoring throughout the trial, which is expected to last until October 2030, with participant involvement potentially extending up to 4.5 years.
Actively Recruiting
This research focuses on adult patients newly diagnosed with myelodysplastic syndrome MDS, aiming to collect epidemiological data across Italy. The study seeks to develop a network of regional registries that use a standardized electronic case report form to store and process anonymous patient data. This network also aims to integrate Italian data with international MDS registries for broader analysis. Participants contribute data to the registry without receiving specific treatments through this study. The data collected will include detailed patient information related to their MDS diagnosis and progression over time. The study spans several years, allowing long-term observation and aggregation of epidemiological data. Throughout the study, researchers will review important outcomes such as the incidence and prevalence of MDS, overall response rates, survival rates, progression to acute myeloid leukemia, and progression-free survival over a six-year period. Participants provide data over time, and the registry helps monitor these outcomes to better understand the disease and its impact.